Risk factors associated with β-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells

Archives of Neurology

Volumn 62, Issue 10, 2005, Pages 1531-1536

  O'Toole, Margot ^a   Janszen, Derek B ^a   Slonim, Donna K ^a,c   Reddy, Padmalatha S ^a   Ellis, Debra K ^a   Legault, Holly M ^a   Hill, Andrew A ^a   Whitley, Maryann Z ^a   Mounts, William M ^a   Zuberek, Krystyna ^a,d   Immermann, Frederick W ^a   Black, Ronald S ^b   Dorner, Andrew J ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

^c Tufts University   (United States)

^d CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; DNA RECOMBINATION; DNA REPAIR; GENE EXPRESSION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MENINGOENCEPHALITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; RISK; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; ENCEPHALITIS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RISK FACTORS; RNA, MESSENGER;

EID: 26444471910     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.10.1531     Document Type: Article

References (24)

1. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994;13:45-53.
2. Schenk DB, Seubert P, Lieberburg I, Wallace J. Beta-peptide immunization: a possible new treatment for Alzheimer disease. Arch Neurol. 2000;57:934-936.
3. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
4. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523-527.
5. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982-985.
6. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-982.
7. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850-8855.
8. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002;8:1263-1269.
9. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94-101.
10. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46-54.
11. Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563-1572.
12. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
13. Burczynski ME, Twine NC, Dukart G, et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res. 2005;11:1181-1189.
14. Hill AA, Brown EL, Whitley MZ, Tucker-Kellogg G, Hunter CP, Slonim DK. Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls. Genome Biol. 2001;2:RESEARCH0055 Epub. Available at: http:// genomebiology.com/2001/2/12/RESEARCH/0055.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;B57:289-300.
16. Xiao Y, Segal MR, Rabert D, et al. Assessment of differential gene expression in human peripheral nerve injury. BMC Genomics. 2002;3:28.
17. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19:368-375.
18. The R Project for Statistical Computing. Available at: www.R-project.org. Accessed December 22, 2004.
19. Ingenuity Web site. Available at: www.Ingenuity.com. Accessed March 3, 2005.
20. Salvador J, Adams EJ, Ershler R, Ershler WB. Future challenges in analysis and treatment of human immune senescence. Immunol Allergy Clin North Am. 2003;23:133-148.
21. Arreaza EE, Gibbons JJ Jr, Siskind GW, Weksler ME. Lower antibody response to tetanus toxoid associated with higher auto-anti-idiotypic antibody in old compared with young humans. Clin Exp Immunol. 1993;92:169-173.
22. Looney RJ, Hasan MS, Coffin D, et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol. 2001;21:30-36.
23. Rey M. [How to manage vaccinations in the elderly traveler] [in French]. Bull Soc Pathol Exot. 1997;90:245-252.
24. Westmoreland D, Player V, Heap DC, Hammond A. Immunization against hepatitis B-what can we expect? results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B. Epidemiol Infect. 1990;104:499-509.